Description
A partial agonist of PPARγ (EC50 = 1.351 μM in a transactivation assay); decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day); decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats at 5 and 10 mg/kg per day; in doxorubicin-resistant K562 human myelogenous leukemia cells, it decreases P-gp levels, increases intracellular accumulation of rhodamine 123, and sensitizes cells to doxorubicin at 25 μM
Formal name: 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
Synonyms: DRF 2593
Molecular weight: 395.4
CAS: 199113-98-9
Purity: ≥98%
Formulation: A crystalline solid